SARS-CoV-2, vaccines and female reproduction: effects on ovarian function

HERRERO Y; VELAZQUE C; HAUK, VANESA; DE ZUÑIGA I; VEIGA F; MARTINEZ G; LAVOLPE M; SCOTTI L; ABRAMOVICH D; PARBORELL F

Mar del Plata

Congreso; Reunión Anual Conjunta de las Sociedades SAIC, SAI y SAFIS; 2022

SAIC

We have previously shown that alterations in ovarian function can be observed up to 9 months after SARS-CoV-2 infection. Until now, no study has evaluated the effect of SARS-CoV-2 infection over longer periods and the effect of vaccines on the female gonad. In the present study, we propose 2 objectives: a) Evaluate ovarian function in patients who have suffered from COVID-19 (mild symptoms) up to 18 months post-infection and b) Evaluate the effect of vaccines against COVID-19 (inactivated virus and adenovirus) on reproductive performance.A total of 125 women (21–43 years old) under ART were recruited between November 2020 and May 2022 from 4 reproductive medicine institutions. For objective a), the patients were classified into: control group (n=30) (no positive test for COVID-19) and post-COVID-19 group (n=55) (at least one positive test by PCR). For objective b), patients are classified into: unvaccinated group (n=70) and group vaccinated for COVID-19 (n=55). The results showed that in patients (without vaccination) the number of retrieved, mature and 2PN oocytes decreased up to 12 months after COVID-19 infection compared to the control regardless of age (p